Delays to reperfusion therapy in acute ST-segment elevation myocardial infarction: results from the AMI-QUEBEC Study
Authors:
- Thao HuynhTHThao Huynh
- Jennifer O'LoughlinJOJennifer O'Loughlin
- Lawrence JosephLJLawrence Joseph
- Erick SchampaertESErick Schampaert
- Stéphane RinfretSRStéphane Rinfret
- Marc AfilaloMAMarc Afilalo
- Simon KouzSKSimon Kouz
- Bernard CantinBCBernard Cantin
- Michel NguyenMNMichel Nguyen
- Mark J. EisenbergMEMark J. Eisenberg
- for the AMI-QUEBEC Study InvestigatorsFIfor the AMI-QUEBEC Study Investigators
Open Access
- 5 December 2006
- journal article
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 175 (12) , 1527-1532
Abstract
Background: Through the AMI-QUEBEC Study we sought to describe delays to reperfusion therapy for ST-segment elevation myocardial infarction (STEMI) and to identify factors associated with prolonged delays. Methods: We reviewed the charts of all consecutive patients with STEMI admitted to 17 hospitals in the province of Quebec in 2003 to obtain data on the time from presentation to reperfusion therapy. Data were available for 1189 (83.0%) of 1432 patients. Results: The median delay to reperfusion therapy was 32 minutes (first and third quartile [Q1, Q3] 20, 49) for 535 patients who received fibrinolytic therapy, 109 minutes (Q1, Q3 79, 150) for 455 patients who underwent primary percutaneous coronary intervention (PCI) at the initial hospital of presentation and 142 minutes (Q1, Q3 115, 194) for 199 patients who underwent primary PCI after an interhospital transfer. Patients who presented outside daytime working hours, those who received primary PCI and those who required interhospital transfer for primary PCI were less likely to receive reperfusion therapy within current recommended times (odds ratios [ORs] 0.49, 0.56 and 0.15, respectively). Increased age was associated with prolonged delays only among patients who received fibrinolytic therapy (OR for each 10-year increase in age 0.95, 95% credible interval [CrI] 0.93–0.99 for fibrinolytic therapy and 0.99, 95% CrI 0.95–1.05, for primary PCI). Interpretation: In 2003, many patients with STEMI in Quebec were not treated within the recommended times. Delays may be reduced by reorganizing pre-and in-hospital care for patients with STEMI to expedite delivery of reperfusion therapy.Keywords
This publication has 32 references indexed in Scilit:
- Effect of Door-to-Balloon Time on Mortality in Patients With ST-Segment Elevation Myocardial InfarctionJACC, 2006
- Door-to-Balloon Time With Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction Impacts Late Cardiac Mortality in High-Risk Patients and Patients Presenting Early After the Onset of SymptomsJACC, 2006
- Relation of Interhospital Delay and Mortality in Patients With ST-Segment Elevation Myocardial Infarction Transferred for Primary Coronary AngioplastyThe American Journal of Cardiology, 2005
- Predictors of intracranial hemorrhage with fibrinolytic therapy in unselected community patients: a report from the FASTRAK II projectAmerican Heart Journal, 2004
- Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything?The American Journal of Cardiology, 2003
- Importance of time-to-reperfusion in patients with acute myocardial infarction with and without cardiogenic shock treated with primary percutaneous coronary interventionAmerican Heart Journal, 2003
- Comparing hierarchical modeling with traditional logistic regression analysis among patients hospitalized with acute myocardial infarction: Should we be analyzing cardiovascular outcomes data differently?American Heart Journal, 2003
- Intracranial Hemorrhage Associated With Thrombolytic Therapy for Elderly Patients With Acute Myocardial InfarctionStroke, 2000
- Workshop: Reimbursement for anticoagulation servicesJournal of Thrombosis and Thrombolysis, 1996
- Bayes FactorsJournal of the American Statistical Association, 1995